[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-345726-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-345726-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","reduction-of-primary-tumor-growth-and-metastasis-in-models-of-triple-negative-breast-cancer-following-tilorone-administration-via-type-i-interferon-signaling","Reduction of primary tumor growth and metastasis in models of triplenegative breast cancer following tilorone administration via type I interferon signaling","","Triple-negative breast cancer (TNBC) shows poorer survival and fewer treatment options than other breast cancer subtypes. Type I interferon (IFN) signaling regulates metastasis and therapeutic response, yet IFN therapies face off-target toxicity that limits clinical translation. Tilorone, an antiviral drug, induces IFN signaling and may enhance BMP signaling. Preclinical testing in metastatic TNBC models evaluates tilorone’s therapeutic effects and mechanistic impact.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/reduction-of-primary-tumor-growth-and-metastasis-in-models-of-triple-negative-breast-cancer-following-tilorone-administration-via-type-i-interferon-signaling/345726/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/reduction-of-primary-tumor-growth-and-metastasis-in-models-of-triple-negative-breast-cancer-following-tilorone-administration-via-type-i-interferon-signaling/345726.png","ImageObject",300,407,{"name":42,"@type":43},"Sage","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why focus on type I interferon signaling in TNBC?","Question",{"text":63,"@type":64},"Type I interferon (IFN) signaling is reported to regulate metastasis and therapeutic response in TNBC. However, toxicity from IFN therapies has limited clinical use.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was tilorone evaluated in the study?",{"text":68,"@type":64},"The study tested tilorone’s effects on multiple TNBC-related cell lines using in vitro assays and compared metastatic burden in mice with orthotopic 4T1.2 tumors using qPCR.",{"name":70,"@type":61,"acceptedAnswer":71},"What were the main findings of tilorone treatment?",{"text":72,"@type":64},"Tilorone increased IFN-stimulated gene expression in 4T1.2 cells, reduced lung metastatic burden, and improved survival. The anti-metastatic effect was blunted in mice lacking the IFNα/β receptor (IFNAR1).","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},345726,1790792178,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":108,"preview_page_count":33,"preview_urls":145},687197207057,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Saunders et al. Breast Cancer Research (2026) 28:119 Breast Cancer Research  \n[https://doi.org/10.1186/s13058-026-02296-7](https://doi.org/10.1186/s13058-026-02296-7)  \nRESEARCH Open Access  \nReduction of primary tumor growth   \nand metastasis in models of triplenegative breast cancer following tilorone administration via type I interferon signaling  \nAlastair A. E. Saunders 1, Kellie A. Mouchemore2,3, Laura Vojtech4, Lauren S. James 1, Thomas B. Chadwick4,5, Lap Hing Chi2,3,4, Chris Karagiannis1, Caroline Bell2,3, Rachel E. Thomson 1, Belinda S. Parker4,5, Robin L. Anderson2,3,6 and Paul Gregorevic1,7,8*  \nAbstract  \nBackground People with triple-negative breast cancer (TNBC) typically have poorer survival than those with other breast cancer subtypes, with fewer treatment options available. Type I interferon (IFN) signaling has been reported as an important regulator of metastasis and therapeutic response inTNBC, but the off-target toxicity of IFN therapies has limited progression to clinical use. Augmenting Bone Morphogenetic Protein (BMP) signaling has also been associated with anti-metastatic effects, but BMP therapies are not clinically available presently. Tilorone is an antiviral drug that induces IFN signaling, which has recently gained added attention as an enhancer of BMP signaling. As an agent capable of enhancing two mechanisms of interest, we therefore aimed to test the therapeutic effects of tilorone in preclinical models of metastatic breast cancer.  \nMethods The effect of tilorone on 4T1 . 2, EMT6 . 5, TBCP-1 and MDA-MB-231-HM cells was studied using multiple in vitro assays. We also compared metastatic burden by qPCR in mice bearing orthotopic 4T1 .2 mammary tumors – a syngeneic and metastatic model ofTNBC – with and without tilorone by unpaired t-tests. The effect oftilorone in combination with 4 mg/kg doxorubicin was tested by a 2-way ANOVA.  \nResults In 4T1 .2 cells, tilorone increased expression of IFN stimulated genes (ISGs) . Tilorone also reduced lung metastatic burden. Improvements in survival associated with tilorone administration were blunted in mice that lacked the IFNα/β receptor (IFNAR1) . The anti-metastatic impact of tilorone was further examined in combination with doxorubicin. In mice bearing 4T1 .2 tumors, and receiving doxorubicin, co-treatment with tilorone increased natural killer (NK) cell maturation in the primary tumor, increased CD4+ & CD8+ T cell activation and NK cell maturation in the pre-metastatic lung, and enhanced metastasis-free survival. Analysis of patient data identified high ISG gene expression in tumors correlated with increased overall survival inTNBC but not in patients with other breast cancer  \n*Correspondence: Paul Gregorevic[pgre@unimelb.edu.au](pgre@unimelb.edu.au)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.0/.)[.](vecommons.org/licenses/by-nc-nd/4.0/.)  \nSa","cbCaieKXvR4MWxEs","https://ap.wps.com/l/cbCaieKXvR4MWxEs","pdf",4092154,16,"English","# Abstract\n# Background\n# Methods\n# Results\n# Conclusions\n# Keywords","[{\"question\":\"Why focus on type I interferon signaling in TNBC?\",\"answer\":\"Type I interferon (IFN) signaling is reported to regulate metastasis and therapeutic response in TNBC. However, toxicity from IFN therapies has limited clinical use.\"},{\"question\":\"How was tilorone evaluated in the study?\",\"answer\":\"The study tested tilorone’s effects on multiple TNBC-related cell lines using in vitro assays and compared metastatic burden in mice with orthotopic 4T1.2 tumors using qPCR.\"},{\"question\":\"What were the main findings of tilorone treatment?\",\"answer\":\"Tilorone increased IFN-stimulated gene expression in 4T1.2 cells, reduced lung metastatic burden, and improved survival. The anti-metastatic effect was blunted in mice lacking the IFNα/β receptor (IFNAR1).\"}]","Reduction of primary tumor growth and metastasis in models of triplenegative breast cancer following tilorone administration via type I interferon signaling | PDF",1790058724,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0dcbd5ea11900cf4f1a898656d3b0d9e.webp",983,1310,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3357271c22e537c59c3dfc6ecfeac9a0.webp",982,1309,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b05e9e9173e659a66222c5e529e0ad4d.webp",981,1308,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/da37259c2182ce0340b0c6bf5129cdb0.webp",980,1306]